Implantable Port Market Size, Share, & Trends Analysis | Global | 2026-2032 | Includes: Power-Injectable Implantable and Non-Power-Injectable Ports

Global Implantable Port Market Report to 2032

The global implantable port market was valued slightly above $430 million in 2025. It is expected to grow at a compound annual growth rate (CAGR) of 3.0%, reaching approximately $530 million by 2032.

This report covers the global market for implantable ports, including non-power-injectable and power-injectable implantable ports used for long-term vascular access.

The analysis includes unit sales, average selling prices (ASPs), procedure numbers, market size, market shares, growth trends, market forecasts through 2032, and historical data back to 2022.

Market growth is supported by the adoption of power-injectable ports, patient preference for fully implanted access, and ongoing design improvements. However, implantation cost, procedural burden, access discomfort, and competition from alternative vascular access devices continue to limit stronger expansion.

Market Overview

The global implantable port market includes long-term vascular access devices implanted beneath the skin. These products are commonly used for patients requiring repeated infusion therapy, including oncology patients receiving chemotherapy.

The market includes power-injectable and non-power-injectable implantable ports. Power-injectable ports can withstand higher pressures than conventional ports, allowing contrast dye injection for computed tomography scan procedures.

If a patient has a conventional implantable port and later requires certain medical imaging workflows, the port may need to be removed and replaced with a power-injectable port. This has supported the shift toward power-injectable technology as a preferred option in many care settings.

Ongoing technological developments are improving the clinical profile of implantable ports and expanding their use cases. Innovation is focused on antimicrobial materials, surface coatings, design improvements, and alternative placement strategies, positioning ports as a more competitive option against PICCs and chronic CVCs in selected indications.

Market Drivers

Power-Injectable Ports

Power-injectable ports are a key driver of the implantable port market. Unit sales of plastic and hybrid power-injectable ports are expected to increase over the forecast period.

These devices support contrast-enhanced imaging workflows and are increasingly expected in many care settings. Their ability to withstand higher injection pressures makes them more flexible for patients who may need both infusion therapy and imaging procedures.

The shift to power-injectable ports has helped stabilize market dynamics by supporting demand for higher-value products. However, this effect is expected to normalize as power-injectable ports become standard of care and the premium commanded by these devices continues to narrow.

Patient Preferences

Patient preference is another important driver. Patients undergoing chemotherapy often want to remain active during treatment, and implantable ports offer lifestyle advantages over external vascular access devices.

Unlike many alternative devices, implantable ports are not visible externally when not accessed. This can make them more appealing to patients who want to maintain daily activities with fewer restrictions.

External devices can limit mobility and may interfere with swimming, showering, or other activities that could dislocate the device or compromise sterility. As the population ages, more potential port patients are expected to have both the need and the means to choose implantable ports over alternative access devices.

Technology and Design Improvements

Technology and design improvements are supporting continued demand for implantable ports. Manufacturers are focusing on features that reduce infection risk, improve access reliability, and support long-term use.

Although implantable ports already have a low infection risk relative to many other vascular access devices, companies are investing in antimicrobial materials, surface coatings, and design enhancements.

Growing interest in alternative placement strategies, including peripheral approaches tailored to specific oncology applications, also reflects efforts to reduce procedural burden. These improvements support clinical preference and help implantable ports remain competitive against PICCs and chronic CVCs.

Market Limiters

Implantation Procedure

The implantation procedure is a significant limiter in the implantable port market. Port placement usually requires a procedure involving anesthesia and operating room time, which makes it more expensive than many alternative vascular access options.

The need for a procedural setting can create barriers for patients, providers, and healthcare systems. This is especially important in cost-sensitive environments where less expensive access devices may be preferred.

Implantation can also result in complications, including infections in patients with compromised immune systems. Although ports generally have favorable infection profiles, procedural risk remains an important factor when deciding between port placement and alternative access methods.

Access Method

Implantable ports are installed beneath the skin and must be accessed through the skin surface using a port needle. This unique access method can create discomfort for some patients.

Penetrating the port requires a significant amount of force, which can be painful. Once the port needle is inserted, it is often left in place during infusion therapy and may cause additional discomfort.

Because of this access experience, some patients may choose alternative vascular access devices. This limits broader adoption, especially when the patient requires frequent access and has concerns about pain or comfort.

Narrowing Power-Injectable Premium

The narrowing price premium for power-injectable ports may limit market value growth. Power capability initially supported higher ASPs because these devices offered a clear functional advantage over conventional ports.

However, as power-injectable ports become standard practice, pricing differentiation is gradually narrowing. This reduces the growth benefit that came from premium feature adoption.

Future market performance will increasingly depend on clinical preference, replacement demand, procedural efficiency, and product differentiation rather than power-injectable conversion alone. This makes it more difficult for manufacturers to rely only on premium pricing to drive value growth.

Market Coverage and Data Scope

• Quantitative coverage: Market size, market shares, procedure numbers, market forecasts, market growth rates, units sold, and average selling prices.
• Qualitative coverage: Market drivers and limiters, competitive analysis, recent mergers and acquisitions, company profiles, product portfolios, and leading competitors.
• Time frame: Base year 2025, forecasts to 2032, and historical data back to 2022.
• Market modeling: Revenue is analyzed using unit sales and ASPs, supported by procedure numbers, competitive share analysis, and forecast assumptions.
• Device scope: The report covers implantable ports used for long-term vascular access, including power-injectable and non-power-injectable ports, single-lumen and double-lumen ports, valved and non-valved ports, and antithrombogenic and conventional device types.

Markets Covered and Segmentation

Implantable Port Market

• Device type: Power-injectable and non-power-injectable.

Power-injectable ports are designed to withstand higher pressures for contrast dye injection during CT imaging procedures. These devices are becoming more common as imaging compatibility becomes an expected feature in many care settings.

Non-power-injectable ports are conventional implantable ports used for infusion therapy and long-term vascular access but not designed for high-pressure contrast injection.

• By lumen: Single lumen and double lumen.

Single-lumen ports support standard infusion needs, while double-lumen ports allow multiple therapies or medications to be delivered through separate access channels.

• By valve type: Valved and non-valved.

Valved ports are designed to reduce blood reflux and related complications, while non-valved ports remain available for cost-sensitive markets and standard use cases.

• Device properties: Antithrombogenic and conventional.

Antithrombogenic ports are designed to reduce thrombus formation, while conventional ports remain widely used in the market.

Each segment is analyzed by market size, market shares, procedure numbers, market forecasts, market growth rates, units sold, and average selling prices.

Competitive Analysis

In 2025, Becton Dickinson maintained its leadership in the global implantable port market through its PowerPort(R) line. The portfolio includes the compact titanium PowerPort(R) Slim and PowerPort(R) MRI(R), which is designed to reduce imaging interference.

BD also offers non-power-injectable products such as the SlimPort(TM) Dual-Lumen Rosenblatt(TM) for multi-medication infusion and the X-Port(TM) for smaller patients. The company further differentiates its offering with valved systems such as AirGuard(TM) and Groshong(TM), which are designed to reduce blood reflux and complications.

AngioDynamics held a significant share of the global implantable port market in 2025. Its portfolio includes Xcela(R) Plus, BioFlo(R), Smart Port(R), Vortex(R), LifePort(R), TitanPort(R), and Triumph-1(R).

The company introduced Smart Port CT(TM) with integrated Vortex(R) technology to enhance drainage and reduce catheter occlusion and infection risk. AngioDynamics also offers the BioFlo Port with Endexo Technology, which uses catheter material designed to resist in-vitro accumulation of blood components compared with non-coated port catheters.

ICU Medical ranked third in the implantable port market in 2025. Its PORT-A-CATH(R) brand is widely recognized, and the newer PORT-A-CATH II(R) model uses a hybrid polysulfone and titanium construction for MRI safety and durability. ICU Medical also offers the P.A.S. PORT(R) arm series and power-injectable ports for chest or arm placement, although arm ports have not gained as much popularity as expected due to catheter pinching concerns.

Technology and Practice Trends

Power-Injectable Port Adoption

Power-injectable ports are becoming standard in many care settings because they support contrast-enhanced CT imaging workflows.

As these devices become more common, their pricing premium is expected to narrow, making future growth more dependent on clinical preference and replacement demand.

Antimicrobial Innovation

Manufacturers are focusing on antimicrobial materials, surface coatings, and design enhancements to reduce infection risk.

Although ports already have a lower infection risk than many alternative vascular access devices, further improvements could strengthen their position against PICCs and chronic CVCs.

Valved Port Systems

Valved ports are designed to reduce blood reflux and related complications. These systems can improve clinical confidence and support differentiation in premium product categories.

Non-valved ports remain relevant in cost-sensitive markets.

Alternative Placement Strategies

Peripheral and arm placement strategies continue to be explored, especially for certain oncology applications. These approaches aim to reduce procedural burden and improve patient options.

However, arm ports have faced adoption challenges due to concerns around catheter pinching based on patient movement and positioning.

Thrombus-Resistant Materials

Technologies such as Endexo are designed to reduce accumulation of blood components on catheter materials. These features may support lower occlusion risk and improve long-term device performance.

Product differentiation in this area may become more important as power-injectable capability becomes standard.

Patient Lifestyle Considerations

Patient lifestyle remains important in port selection. Implantable ports are not visible externally when not accessed, which can improve comfort, mobility, and daily activity for patients receiving long-term therapy.

This supports continued preference for ports among patients who want less visible access and fewer daily restrictions.

Geography

This report provides global coverage across North America, Europe, Asia-Pacific, Latin America, the Middle East, and Africa.

Why This Report

• How large is the global implantable port market today, and how much is it expected to grow through 2032?
• How are unit sales, procedure numbers, ASPs, and market values changing over time?
• How are power-injectable ports changing product mix and imaging compatibility?
• Why is the pricing premium for power-injectable ports narrowing?
• How do patient preferences support the use of implantable ports over external vascular access devices?
• What role do antimicrobial materials, coatings, and design improvements play in port innovation?
• How do valved, non-valved, single-lumen, and double-lumen ports differ in market demand?
• What barriers are created by the implantation procedure and port access method?
• Which companies lead the global implantable port market?
• How are BD, AngioDynamics, and ICU Medical positioned across power-injectable, non-power-injectable, valved, and specialty port categories?

The Global Implantable Port Market Report from iData Research answers these questions with device-level analysis, procedure-based modeling, ASP data, company share insights, and forecasts through 2032. Use it to evaluate demand, benchmark competitors, understand power-injectable adoption, and support commercial planning in the global implantable port market.